1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. News
  7. Summary
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exelixis Reports Trial Results For Cabozantinib in Combination With Immunotherapies to Treat Colorectal Cancer

01/19/2022 | 03:17pm EDT


ę MT Newswires 2022
All news about EXELIXIS, INC.
05/11TRANSCRIPT : Exelixis, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11..
CI
05/10TRANSCRIPT : Exelixis, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10Exelixis Q1 Non-GAAP EPS, Revenue Higher; Reiterates 2022 Guidance
MT
05/10EXELIXIS : Q1 Earnings Snapshot
AQ
05/10EXELIXIS, INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
05/10Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
BU
05/10Earnings Flash (EXEL) EXELIXIS Posts Q1 EPS $0.26, vs. Street Est of $0.23
MT
05/10Earnings Flash (EXEL) EXELIXIS Reports Q1 Revenue $356M, vs. Street Est of $363.2M
MT
05/10Exelixis, Inc. Reports Earnings Results for the First Quarter Ended April 01, 2022
CI
05/10Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2022
CI
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Financials (USD)
Sales 2022 1 587 M - -
Net income 2022 291 M - -
Net cash 2022 1 276 M - -
P/E ratio 2022 22,6x
Yield 2022 -
Capitalization 6 498 M 6 498 M -
EV / Sales 2022 3,29x
EV / Sales 2023 2,73x
Nbr of Employees 954
Free-Float 97,7%
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | MarketScreener
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 20,26 $
Average target price 26,53 $
Spread / Average Target 31,0%
EPS Revisions
Managers and Directors
Michael M. Morrissey President-Research & Development
Christopher J. Senner Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Vicki L. Goodman Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
EXELIXIS, INC.10.83%6 429
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-16.67%43 023
BIONTECH SE-38.39%38 601